Mark Brantly

13.3k total citations
187 papers, 8.7k citations indexed

About

Mark Brantly is a scholar working on Molecular Biology, Cancer Research and Oncology. According to data from OpenAlex, Mark Brantly has authored 187 papers receiving a total of 8.7k indexed citations (citations by other indexed papers that have themselves been cited), including 78 papers in Molecular Biology, 78 papers in Cancer Research and 42 papers in Oncology. Recurrent topics in Mark Brantly's work include Protease and Inhibitor Mechanisms (76 papers), Peptidase Inhibition and Analysis (40 papers) and Blood Coagulation and Thrombosis Mechanisms (27 papers). Mark Brantly is often cited by papers focused on Protease and Inhibitor Mechanisms (76 papers), Peptidase Inhibition and Analysis (40 papers) and Blood Coagulation and Thrombosis Mechanisms (27 papers). Mark Brantly collaborates with scholars based in United States, United Kingdom and Ireland. Mark Brantly's co-authors include Ronald G. Crystal, Toshihiro Nukiwa, James K. Stoller, Farshid N. Rouhani, Terence R. Flotte, Mark Holmes, Michael Courtney, David T. Curiel, Charlie Strange and Noel G. McElvaney and has published in prestigious journals such as Science, New England Journal of Medicine and Proceedings of the National Academy of Sciences.

In The Last Decade

Mark Brantly

181 papers receiving 8.4k citations

Peers

Countries citing papers authored by Mark Brantly

Since Specialization

Citations

This map shows the geographic impact of Mark Brantly's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Brantly with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Brantly more than expected).

Fields of papers citing papers by Mark Brantly

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Brantly. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Brantly. The network helps show where Mark Brantly may publish in the future.

Co-authorship network of co-authors of Mark Brantly

This figure shows the co-authorship network connecting the top 25 collaborators of Mark Brantly. A scholar is included among the top collaborators of Mark Brantly based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Brantly. Mark Brantly is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Pioglitazone reduces hepatic α-1 antitrypsin accumulation through autophagy and AMPK activation in α-1 antitrypsin-deficient mice 2025 ·American Journal of Physiology-Gastrointestinal and Liver Physiology ·Yuanqing Lu, (unknown), (unknown), (unknown), Chalermchai Khemtong, Kenneth Cusi, Mark Brantly, Nazli Khodayari	1
2	Review article: New developments in biomarkers and clinical drug development in alpha‐1 antitrypsin deficiency‐related liver disease 2024 ·Alimentary Pharmacology & Therapeutics ·Rohit Loomba, (unknown), Jeffrey Teckman, Veeral Ajmera, Cynthia Behling, Mark Brantly, David A. Brenner, Jeanine D’Armiento, Michael Fried, Janani Iyer, Mattias Mandorfer, Don C. Rockey, Monica A. Tincopa, Raj Vuppalanchi, Zobair M. Younossi, Aleksander Krag, Alice Turner, Pavel Strnad	3
3	Recombinant Alpha-1 Antitrypsin–Fc Fusion Protein INBRX-101 in Adults With Alpha-1 Antitrypsin Deficiency: A Phase 1 Study 2024 ·Chronic Obstructive Pulmonary Diseases Journal of the COPD Foundation ·Mark Brantly, Brooks Kuhn, (unknown), Ravi Mahadeva, (unknown), Catherina L. Chang, Cynthia D. Brown, Michael Campos, Jorge Lascano, (unknown), (unknown), (unknown), (unknown), (unknown), James Kalabus, Brendan P. Eckelman, (unknown)	5
4	Sirtuin3 promotes the degradation of hepatic Z alpha-1 antitrypsin through lipophagy 2024 ·Hepatology Communications ·(unknown), (unknown), Zhiguang Huo, (unknown), (unknown), (unknown), Virginia Clark, Thiago Beduschi, Ali Zarrinpar, Mark Brantly, Nazli Khodayari	2
5	Lung microhaemorrhage drives oxidative/inflammatory damage in α₁-antitrypsin deficiency 2023 ·ERJ Open Research ·Cesare Saltini, (unknown), Yan Ping Xin, (unknown), Andrew J. Ghio, Craig G. Moneypenny, Alberto Riva, Dongtao Fu, Tammy Flagg, (unknown), Ivan Arisi, Kristianna M. Fredenburg, Yang Zhang, Jorge Lascano, Mark Brantly	2
6	Testing Patterns and Disparities for Alpha-1 Antitrypsin Deficiency 2023 ·The American Journal of Medicine ·(unknown), (unknown), Mark Brantly, Jorge Lascano	2
7	Augmentation Therapy Modulates Systemic Inflammation in Individuals with Alpha-1 Antitrypsin Deficiency and Chronic Obstructive Pulmonary Disease 2023 ·Chronic Obstructive Pulmonary Diseases Journal of the COPD Foundation ·Jorge Lascano, (unknown), Nazli Khodayari, Mark Brantly	4
8	Alpha-defensins inhibit ERK/STAT3 signaling during monocyte-macrophage differentiation and impede macrophage function 2023 ·Respiratory Research ·Jungnam Lee, (unknown), Yuanqing Lu, (unknown), (unknown), Mark Brantly	3
9	Correlation of alpha-1 antitrypsin levels and exosome associated neutrophil elastase endothelial injury in subjects with SARS-CoV2 infection 2022 ·PLoS ONE ·Jorge Lascano, (unknown), (unknown), (unknown), Qiang Xiao, Tammy Flagg, Yogesh Scindia, Borna Mehrad, Mark Brantly, Nazli Khodayari	12
10	Nicotine Exacerbates TAAD Formation Induced by Smooth Muscle-Specific Deletion of the TGF-β Receptor 2 2021 ·Journal of Immunology Research ·(unknown), Xiaoyan Qi, Fen Wang, (unknown), (unknown), (unknown), Mark Brantly, Gilbert R. Upchurch, Zhihua Jiang	9
11	Neutrophil elastase promotes macrophage cell adhesion and cytokine production through the integrin-Src kinases pathway 2020 ·Scientific Reports ·Karina Krotova, Nazli Khodayari, (unknown), George Aslanidi, Mark Brantly	49
12	Targeting the site encoded by SERPINA1E342K for treating alpha‐1 antitrypsin deficiency‐associated liver diseases 2019 ·FEBS Letters* ·Xiaojuan Zhang, Kien Pham, (unknown), Ryan J. Schutte, Mark Brantly, Chen Liu, David A. Ostrov	3
13	A Novel Small Molecule Inhibits Intrahepatocellular Accumulation of Z-Variant Alpha 1-Antitrypsin In Vitro and In Vivo 2019 ·Cells ·Xiaojuan Zhang, Kien Pham, (unknown), Ryan J. Schutte, David Hernández Gonzalo, Penghui Zhang, (unknown), Weihong Tan, Mark Brantly, Chen Liu, David A. Ostrov	13
14	Emergency myelopoiesis contributes to immune cell exhaustion and pulmonary vascular remodelling 2019 ·British Journal of Pharmacology ·Chunhua Fu, Yuanqing Lu, M. Williams, Mark Brantly, Corey E. Ventetuolo, Laurence Morel, Borna Mehrad, Edward W. Scott, Andrew J. Bryant	12
15	The Diagnosis and Management of Alpha-1 Antitrypsin Deficiency in the Adult 2016 ·Chronic Obstructive Pulmonary Diseases Journal of the COPD Foundation ·Robert A. Sandhaus, Gerard Turino, Mark Brantly, Michael Campos, Carroll E. Cross, Kenneth W. Goodman, D. Kyle Hogarth, Shandra L. Knight, James Stocks, James K. Stoller, Charlie Strange, Jeffrey Teckman	140
16	Safety and Pharmacokinetics of 120 mg/kg versus 60 mg/kg Weekly Intravenous Infusions of Alpha-1 Proteinase Inhibitor in Alpha-1 Antitrypsin Deficiency: A Multicenter, Randomized, Double-Blind, Crossover Study (SPARK) 2013 ·COPD Journal of Chronic Obstructive Pulmonary Disease ·Michael Campos, Friedrich Kueppers, James Stocks, Charlie Strange, Junliang Chen, (unknown), (unknown), Mark Brantly	44
17	Biochemical Efficacy and Safety of a New, Ready-to-Use, Liquid Alpha-1-Proteinase Inhibitor, GLASSIA (Alpha ₁ -Proteinase Inhibitor (Human), Intravenous) 2013 ·COPD Journal of Chronic Obstructive Pulmonary Disease ·Robert A. Sandhaus, James Stocks, Farshid N. Rouhani, Mark Brantly, (unknown)	15
18	In vivo post-transcriptional gene silencing of α-1 antitrypsin by adeno-associated virus vectors expressing siRNA 2007 ·Laboratory Investigation ·Pedro E. Cruz, Christian Mueller, Travis Cossette, (unknown), Qiushi Tang, Stuart G. Beattie, Mark Brantly, Martha Campbell‐Thompson, Keith Blomenkamp, Jeffrey Teckman, Terence R. Flotte	44
19	Multi-Center Study: The Biochemical Efficacy, Safety and Tolerability of a New α₁-Proteinase Inhibitor, Zemaira 2006 ·COPD Journal of Chronic Obstructive Pulmonary Disease ·James Stocks, Mark Brantly, (unknown), Alan R. Barker, Friedrich Kueppers, Charlie Strange, James F. Donohue, Robert A. Sandhaus	40
20	COMPARABLE PHARMACOKINETIC PROPERTIES OF TWO ALPHA1-PROTEINASE INHIBITORS AFTER SINGLE THERAPEUTIC DOSES 2005 ·CHEST Journal ·James Stocks, Mark Brantly, Alan R. Barker, Friedrich Kueppers, Charlie Strange, James F. Donohue, Robert A. Sandhaus	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact